Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DURECT CORPDRRX · Entity 75335 | Director | December 07, 2021 | December 09, 2021 |
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DURECT CORP
Report date December 07, 2021 · Filed December 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,000 |
Reported balance
After 2021-12-07 transaction · row 1
1 source rowRow 1 · 2021-12-07 · Purchase · Acquired 20,000 · Balance 105,000 |
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001273306-26-000001 · wk-form4_1779393978.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 41,800 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001273306-26-000001 · wk-form4_1779393978.xml · derivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2036-05-20 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 20, 2027. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000037 · wk-form4_1747861076.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000037 · wk-form4_1747861076.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:50 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000036 · wk-form4_1716410996.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 2,167 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:50 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 2,917 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001055726-24-000036 · wk-form4_1716410996.xml · derivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 2,917 shares Expires 2034-05-21 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 21, 2025. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000033 · wk-form4_1715893916.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000033 · wk-form4_1715893916.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:52 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000035 · wk-form4_1684270316.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:52 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000035 · wk-form4_1684270316.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:52 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000035 · wk-form4_1684270316.xml · derivative · entry 4 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:52 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 35,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001055726-23-000035 · wk-form4_1684270316.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-15 F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Options to vest 100% on May 15, 2024. Read SEC document |
| July 20, 2022 Filed Jul 20, 2022 20:16 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001055726-22-000045 · wf-form4_165834817873235.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires 2022-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| July 20, 2022 Filed Jul 20, 2022 20:16 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,000 | $2.25 | $4,500.00 |
DisclosureSEC source: 0001055726-22-000045 · wf-form4_165834817873235.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 20, 2022 Filed Jul 20, 2022 20:16 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,000 | $2.20 | $4,400.00 |
DisclosureSEC source: 0001055726-22-000045 · wf-form4_165834817873235.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 28,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001055726-22-000038 · wf-form4_165281912007418.xml · derivative · entry 4 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-16 F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Options to vest 100% on May 16, 2023. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000038 · wf-form4_165281912007418.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000038 · wf-form4_165281912007418.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000038 · wf-form4_165281912007418.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001055726-22-000025 · wf-form4_164754740182512.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires 2022-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,000 | $3.16 | $6,320.00 |
DisclosureSEC source: 0001055726-22-000025 · wf-form4_164754740182512.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,000 | $2.20 | $4,400.00 |
DisclosureSEC source: 0001055726-22-000025 · wf-form4_164754740182512.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001055726-22-000003 · wf-form4_164279896827793.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,000 shares Expires 2022-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,000 | $4.27 | $8,540.00 |
DisclosureSEC source: 0001055726-22-000003 · wf-form4_164279896827793.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,000 | $2.20 | $4,400.00 |
DisclosureSEC source: 0001055726-22-000003 · wf-form4_164279896827793.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 13:35 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 20,000 | $1.02 | $20,360.00 |
DisclosureSEC source: 0001209191-21-068679 · doc4.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:31 UTC | DURECT CORP DRRX · Entity 75335 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001209191-21-040920 · doc4.xml · derivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: 100% of the total shares subject to this grant dated June 15, 2021 shall vest on the day before the first year anniversary of the grant date. Read SEC document |
| May 17, 2021 Filed May 17, 2021 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 3,045 | $6.62 | $20,157.90 |
DisclosureSEC source: 0001055726-21-000044 · wf-form4_162128318356430.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,305 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000044 · wf-form4_162128318356430.xml · derivative · entry 5 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000044 · wf-form4_162128318356430.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000044 · wf-form4_162128318356430.xml · derivative · entry 4 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 27,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001055726-21-000044 · wf-form4_162128318356430.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2031-05-13 F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Options to vest 100% on May 13, 2022. Read SEC document |
| April 16, 2021 Filed Apr 16, 2021 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001055726-21-000035 · wf-form4_161860751450487.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2021-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| April 16, 2021 Filed Apr 16, 2021 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,000 | $8.75 | $17,500.00 |
DisclosureSEC source: 0001055726-21-000035 · wf-form4_161860751450487.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 16, 2021 Filed Apr 16, 2021 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,000 | $3.56 | $7,120.00 |
DisclosureSEC source: 0001055726-21-000035 · wf-form4_161860751450487.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 20:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001055726-21-000028 · wf-form4_161592807371336.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2021-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 20:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,000 | $10.41 | $20,820.00 |
DisclosureSEC source: 0001055726-21-000028 · wf-form4_161592807371336.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 20:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,000 | $3.56 | $7,120.00 |
DisclosureSEC source: 0001055726-21-000028 · wf-form4_161592807371336.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001055726-21-000009 · wf-form4_161369307299569.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires 2021-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,000 | $14.68 | $29,360.00 |
DisclosureSEC source: 0001055726-21-000009 · wf-form4_161369307299569.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,000 | $3.56 | $7,120.00 |
DisclosureSEC source: 0001055726-21-000009 · wf-form4_161369307299569.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Options · Derivative | 2,750 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001055726-21-000001 · wf-form4_160988089526905.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,750 shares Expires 2021-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 2,750 | $9.00 | $24,750.00 |
DisclosureSEC source: 0001055726-21-000001 · wf-form4_160988089526905.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,750 | $3.56 | $9,790.00 |
DisclosureSEC source: 0001055726-21-000001 · wf-form4_160988089526905.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:36 UTC | DURECT CORP DRRX · Entity 75335 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001082038-20-000007 · edgardoc.xml · derivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: 100% of the total shares of this Grant Dated June 17, 2020 shall vest on the day before the first year anniversary of the Grant Date. Read SEC document |
| May 20, 2020 Filed May 20, 2020 21:37 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 8,750 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001055726-20-000040 · wf-form4_159001065342841.xml · derivative · entry 3 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2020-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Given effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Given effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · derivative.underlying_shares: Given effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| May 20, 2020 Filed May 20, 2020 21:37 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 8,750 | $15.95 | $139,594.00 |
DisclosureSEC source: 0001055726-20-000040 · wf-form4_159001065342841.xml · nonDerivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,650 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.64 to $16.19, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 20, 2020 Filed May 20, 2020 21:37 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,750 | $4.60 | $40,250.00 |
DisclosureSEC source: 0001055726-20-000040 · wf-form4_159001065342841.xml · nonDerivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000036 · wf-form4_158957320617701.xml · derivative · entry 2 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock · 8,700 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 13,300 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001055726-20-000036 · wf-form4_158957320617701.xml · derivative · entry 1 BENITO SIMON X · CIK 0001273306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2030-05-14 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.